DOSING FOR TREATMENT WITH ANTI-TIGIT AND ANTI-PD-L1 ANTAGONIST ANTIBODIES

• Main Authors: CHA, Edward Namserk, BARAK, Hila, ZHANG, Xiaosong, CHAN, Hui Min Phyllis, HOANG, Tien, WU, Benjamin, MENDUS, Diana, MENG, Raymond D, STEVENS, Heather Blythe, LAU, Janet
• Format: Patent
• Language: English; French
• Published: 30.09.2021
• Subjects: CHEMISTRY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The invention provides methods of dosing for the treatment of cancers. In particular, provided are methods, compositions, uses, and kits for treating subjects having cancer by administering an anti-TIG IT antagonist antibody (e.g., an anti-TIG IT antagonist antibody as disclosed herein, e.g., tiragolumab) and a PD-1 axis binding antagonist (e.g., an anti-PD-L1 antagonist antibody (e.g., atezolizumab)). L'invention concerne des procédés de dosage pour le traitement de cancers. En particulier, l'invention concerne des procédés, des compositions, des utilisations et des kits pour traiter des sujets atteints d'un cancer par administration d'un anticorps antagoniste de l'IT anti-TIG (par ex., un anticorps antagoniste de l'IT anti-TIG tel que décrit ici, par ex., le tiragolumab) et un antagoniste de liaison à l'axe PD-1 (par ex., un anticorps antagoniste anti-PD-L1 (par ex., l'atzolizumab)).